[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][Branch1][O][C][C][N][C][C][C][C][C][Ring1][=Branch1][Branch1][=Branch2][C][=C][C][=C][C][=C][Ring1][=Branch1][O]"}, {"from": "gpt", "value": "The molecule is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders. Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as [levodopa].  Trihexyphenidyl was granted FDA approval on 13 May 1949."}]